Relay Therapeutics (RLAY) Accumulated Depreciation & Amortization (2020 - 2025)
Relay Therapeutics (RLAY) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $21.5 million as the latest value for Q4 2025.
- Quarterly Accumulated Depreciation & Amortization fell 25.47% to $21.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.5 million through Dec 2025, down 25.47% year-over-year, with the annual reading at $21.5 million for FY2025, 25.47% down from the prior year.
- Accumulated Depreciation & Amortization for Q4 2025 was $21.5 million at Relay Therapeutics, down from $28.9 million in the prior quarter.
- The five-year high for Accumulated Depreciation & Amortization was $28.9 million in Q4 2024, with the low at $14.4 million in Q4 2021.
- Average Accumulated Depreciation & Amortization over 5 years is $21.4 million, with a median of $21.5 million recorded in 2025.
- The sharpest move saw Accumulated Depreciation & Amortization skyrocketed 36.44% in 2021, then fell 25.47% in 2025.
- Over 5 years, Accumulated Depreciation & Amortization stood at $14.4 million in 2021, then grew by 27.99% to $18.4 million in 2022, then rose by 28.24% to $23.6 million in 2023, then increased by 22.6% to $28.9 million in 2024, then dropped by 25.47% to $21.5 million in 2025.
- According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $21.5 million, $28.9 million, and $23.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.